Challenges and resistance mechanisms to EGFR targeted therapies in head and neck cancers and breast cancer: Insights into RTK dependent and independent mechanisms (IMAGE)
Caption
Figure 6: Mechanism of Anti-EGFR resistance in head and neck cancer by activation of TLR4-MyD88 signaling. EGFR inhibition by cetuximab prevents Src activation, thus preventing MyD88 degradation, leading to activation of TLR4 signaling via NFKB, leading to production of anti-apoptotic and pro-tumor inflammatory proteins that promote cancer cell survival. Created with https://www.biorender.com/.
Credit
Copyright: © 2025 Shyamsunder et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Usage Restrictions
With credit to the original source.
License
Original content